“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
Dr. Stevan Djuric is currently President of a Medicinal Chemistry Consulting company - Discovery Chemistry and Technology Consulting LLC, based in North Carolina, USA. Previously, he was Vice President, Discovery Chemistry and Technology, Global Pharmaceutical Research and Development at AbbVie, Illinois, USA, and head of their global Medicinal Chemistry Leadership Team. He was also responsible for the Discovery Chemistry and Technology organization within their Discovery organization and chemistry outsourcing activities.
That group’s efforts were focused on new initiatives in the areas of high throughput synthesis and purification, DNA encoded library design and production, covalent fragment library design and production, hit to lead chemistry, chemical biology including target identification proteomics, protein degradation, Structural Biology, Cheminformatics, chemistry outsourcing activities, and new enabling technology identification and development. He was named an AbbVie Distinguished Research Fellow in 2015 and was a member of their governing Scientific Governing Board (chaired by the CSO—the highest level of scientific achievement in the Company). During his tenure at Abbott/AbbVie Laboratories, Dr. Djuric was a Project Leader for groups in the Immunoscience, Metabolic Disease, Antiinfective, and CNS areas.
Several of these programs have advanced compounds into clinical development (e.g., DPPIV inhibitor ABT-279) and to the market, including Abbott’s proprietary rapamycin analog, Zotarolimus, currently licensed to Medtronics for use on their vascular stents, marketed in the United States and Europe. More recently, compounds from his team’s medicinal chemistry efforts have entered advanced clinical trials (Phase 3) in the CNS and Cystic Fibrosis areas, including the recently approved ABBV-951 pump, PRODUOPA. He and his team received two President’s awards for notable technology achievements during his tenure.
These awards are the highest level scientific awards within AbbVie research. Dr Djuic has over 180 scientific publications, presentations, and patents/applications pending. He has also given over 50 invited lectures at universities and scientific meetings. Currently, he is a member of several Editorial Advisory Boards, including the Journal of Medicinal Chemistry, and is an Associate Editor for ACS Medicinal Chemistry Letters. He also serves on the Scientific Advisory Boards of several pharma/biopharma companies. In addition, he has held adjunct faculty positions in the School of Pharmacy at the University of Kansas at Lawrence, USA (10 years) and in the School of Pharmacy at the High Point University, NC.
